SFTBY
by Anonymous Questions | November 23, 2014 11:31 am
On March 19, 2014 Travis Johnson wrote an article about SFTBY as a way to get in on the BABA IPO[1].
I would like his opinion as to why SFTBY, a 32% stakeholder in BABA has not moved up in view of the current BABA price of $110; A 70% increase since the IPO was issued.
Thank You
Endnotes:
- IPO: https://www.stockgumshoe.com/tag/ipo/
Source URL: https://www.stockgumshoe.com/2014/11/microblog-sftby/
The answer IMO is simple, there is no financial good data showing its performance and dividend to attract traders. Only $0.06 cash div. in Sept last declaration with Gross Yield 0.57% is the factor behind no increase. However watch in Feb 2015.
I AM A SUB SCRIBER TO YOUR PERIODICAL AND AM VERY INTERESTED IN YOUR STANSBERRY VENTURE. HOW DO I INVEST IN THIS COMPANY. THE ARTICLE IS ABOUT A DRUG THAT WILL REDUCE/ELININATE PAIN.
TOMLINHARES
We don’t publish Stansberry Venture, but we did write about one of their ads here: http://www.stockgumshoe.com/reviews/stansberry-venture/whats-stansberry-venture-1/ — it wasn’t a pain medicine, but perhaps there have been more recent ads that I’ve not yet seen.
Softbank has had other problems — their core business at home is in Yen, which makes performance looks worse in dollars, and their investment in US telecom (they own Sprint) is expensive and they were unable to get the green light from regulators to take over T-Mobile and become a real competitor to Verizon and AT&T.
I said I’d prefer Softbank to Yahoo as an Alibaba play largely because Softbank owned more of BABA and wasn’t planning to sell, which is still true, but their other businesses are disappointing.
Travis — Watched a documentary Sunday about ALS and Ismed — a biopharmaceutical out of NJ that had supposed great success with a treatment for ALS, but, alas the good ole’ FDA would only grant VERY few patients access to the treatment (guess protocol is a better term) Wondering if you or Dr. KSS have any thoughts on the company or it’s research–Thanks–All The Best!
Company is Insmed–please excuse the typo